4.8 Article

Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication

期刊

IMMUNITY
卷 55, 期 6, 页码 1032-+

出版社

CELL PRESS
DOI: 10.1016/j.immuni.2022.05.013

关键词

-

资金

  1. Italian Foundation for Cancer Research [AIRC 19903]
  2. Telethon [GGP17094]
  3. Prin [2017BZEREZ]
  4. Italian Multiple Sclerosis Foundation [FISM 2019/R-single/012]
  5. US National Institutes of Health [R01AI150297]

向作者/读者索取更多资源

This study identifies a previously unrecognized metabolic communication pathway, in which cDC1 cells extend their immunoregulatory capacity to cDC2 through the production of L-kynurenine. This finding has potential therapeutic implications in treating autoimmune demyelinating diseases.
Conventional dendritic cells (cDCs), cDC1 and cDC2, act both to initiate immunity and maintain self-tolerance. The tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is used by cDCs in maintaining tolerance, but its role in different subsets remains unclear At homeostasis, only mature CCR7(+) cDC1 expressed IDO1 that was dependent on IRF8. Lipopolysaccharide treatment induced maturation and IDO1-dependent tolerogenic activity in isolated immature cDC1, but not isolated cDC2. However, both human and mouse cDC2 could induce IDO1 and acquire tolerogenic function when co-cultured with mature cDC1 through the action of cDC1-derived L-kynurenine. Accordingly, cDC1-specific inactivation of IDO1 in vivo exacerbated disease in experimental autoimmune encephalomyelitis. This study identifies a previously unrecognized metabolic communication in which IDO1-expressing cDC1 cells extend their immunoregulatory capacity to the cDC2 subset through their production of tryptophan metabolite L-kynurenine. This metabolic axis represents a potential therapeutic target in treating autoimmune demyelinating diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据